2014—2019年某医院尿路感染病原菌分布及耐药情况

doi:10.19739/j.cnki.issn1001-9510.2021.02.009

Abstract
Figure/Table
References (19)
Related Citation (8)

Download: PDF (844 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To analyze the distribution and drug resistance of pathogenic bacteria generated from urine culture in a Hospital from 2014 to 2019, so as to provide basis for the correct clinical application of antimicrobial agents.Methods The pathogenic bacteria found in urine culture from 2014 to 2019 were collected, and their distribution and drug sensitivity were analyzed.Results Totally 2 363 strains of pathogenic bacteria were isolated, including 1 480 (62.6%) strains of gram-negative bacteria, 502 (21.2%) strains of gram-positive bacteria, and fungi 381 (16.1%); the detection rate of Escherichia coli was the highest, accounting for 37.7% of the total number of pathogens detected. The drug resistance rate of most cephalosporins and quinolones was above 40%, with no significant change in the last six years. The drug resistance rate of enzyme inhibitors and carbapenems has not increased significantly in the past six years and is still at a low level, below 6%. The ESBL strains in Klebsiella pneumoniae and Proteus singular were 49% and 50% respectively, and the drug resistance rates of Escherichia coli, Klebsiella pneumoniae and Proteus singular to imipenem were 0.8%, 1.4% and 2.4% respectively. The drug resistance rates of Pseudomonas aeruginosa to imipenem and amtriaxone were 11% and 14% respectively. The drug resistance rate of Enterococcus faecalis was higher than that of enterococcus faecalis, and all of them were more sensitive to linezolid, tekoranin and vancomycin. The drug resistance rates of Staphylococcus epidermidis to benzoxicillin and penicillin were 60% and 86.7% respectively. The sensitivity to vancomycin was 100%. The highest resistance rate of fungi to itraconazole was 17.6%, and no resistance to 5-fluorocytosine was found.Conclusion The results of this study showed that gram-negative bacteria were dominant in urine culture, mainly Escherichia coli, and cefoperazine, piperacillin/tazobactam and cefoperazone/sulbactam could be used as initial empirical drugs in clinical practice.

Key words： urinary tract infection drug-resistant pathogen

Received: 26 August 2020

PACS:

R446.5

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	DONG Li
	PENG Xinguo
	JI Bing

Cite this article:

DONG Li,PENG Xinguo,JI Bing. Distribution and drug resistance of pathogenic bacteria in urinary tract infection in a hospital from 2014 to 2019[J]. 滨州医学院学报, 2021, 44(2): 116-120.

URL:

http://manu58.magtech.com.cn/Jwk_bzyxy/EN/10.19739/j.cnki.issn1001-9510.2021.02.009 OR http://manu58.magtech.com.cn/Jwk_bzyxy/EN/Y2021/V44/I2/116

[1] ANA L F M, JENNIFER N W, MICHAEL C, et al. Urinary tract infections: Epidemiology, mechanisms of infection and treatment options[J]. Nat Rev Microbiol, 2015, 13(5): 269-284.
[2] 1WILSON G, BADARUDEEN S, GODWIN A. Antibiotic screening of urine culture as a useful quality audit[J]. Journal of Infection in Developing Countries, 2011, 5(4):299-302.
[3] 宋春伟.尿路感染病原菌分布及耐药性分析[J].医学理论与实践,2019,32(13):2101-2103.
[4] 张洁.尿路感染病原菌分布及耐药性分析[J].中国感染控制杂志,2015,14(1):68-69.
[5] 王艳,吴俊,梁倩,等.2016—2018年北京某三甲医院中段尿培养的病原菌构成与耐药性分析[J/OL].中国抗生素杂志:1-6[2020-06-07].
[6] AYELING B,ABEBE B,SHIBESHI A,et al.Bacterial isolates and their an antimicrobial susceptibility patterns among pediatric patients with urinary tract infections[J].Turki J Urol,2018,44(1):62-69.
[7] 胡付品,郭燕,朱德妹,等.2018年CHINET中国细菌耐药性监测[J].中国感染与化疗杂志,2020,20(1):1-10.
[8] 胡付品,郭燕,朱德妹,等.2019年CHINET三级医院细菌耐药监测[J].中国感染与化疗杂志,2020,20(3):233-243.
[9] VILLAR H E, DANEL F,LIVERMORE D M. Permeability to carbapenems of Proteus mirabilis mutants selected for resistance to imipenem or other beta-lactams[J]. J Antimicrob Chemother,1997,40(3):365-370.
[10] ELIKBILEK N,G ZALAN A,ZDEM B,et al.Extended-spectrum beta-lactamase production by Enterobacteriaceae isolates fromurine cultures of outpatients: results of a 7-year follow-up[J].Mikrobiyol Bul,2015,49(2):259-265.
[11] CARMELI Y,TROILLET N,ELIOPOULOS G M, et al.Emergence of antibiotic-resistant Pseudomonas aeruginosa:comparison of risks associated with different antipseudomonal agents[J].Antimicrob Agents Chemother,1999,43(8):1397-1382.
[12] 周芳,王丽红,孙晓茜,等.铜绿假单胞菌耐药性与抗菌药物使用强度的相关性分析[J].中国现代医药杂志,2020,22(3):45-48.
[13] 谈昀,马勇智,雷方,等.2014—2018年临床患者送检样本肠球菌的菌种分布及耐药性分析[J].现代检验医学杂志,2019,34(6):93-96.
[14] UYEN G J,AUSUBEL F M.Enterococcus infection biology:lessons from inver tebrate host models[J].J Mincrobiol,2014,52(3):200-210.
[15] KOMATSUZAWA H,CHOI G H,OHTA K,et al.Cloning and characterization of a gene,pbpF,encoding a new penicillin-binding protein,PBP2B,in staphylococcus aureus[J].Antimicrob Agents Chemocher,1999,43(7):1578-1583.
[16] 黄郑雨,廖国建.抗真菌耐药性的全球问题:流行、机制与管理[J].国外医药(抗生素分册),2018,39(5):357-362.
[17] 赵红梅,彭新国,纪冰,等.医院感染的金黄色葡萄球菌多重耐药机制研究磁[J].滨州医学院学报,2014,37(3):175-177.
[18] BASSETTI M, GARNACHO-MONTERO J, CALANDRA T A, et al.Intensive care medicine research agenda on invasive fungal infection in critically ill patients[J]. Intensive Care Med,2017,43(9):1225-1238.
[19] MAUBON D, GARNAUD C, CALANDRA T, et al. Resistance of Candida spp. to antifungal drugs in the ICU: where are we now?[J]. Intensive Care Med, 2014, 40(9):1241-1255.